₹ 8.2 Cr
Volume transacted
11.9 K
stocks traded
Last Updated time: 27 Jul 13:03 PM
Dr Reddys Laboratories Ltd
NSE: DRREDDY
DPS
₹ 40
Last updated : FY 2024
The Dividend per Share of Dr Reddys Laboratories Ltd is ₹ 40 as of 2024 .a1#The Dividend Payout of Dr Reddys Laboratories Ltd changed from 25.99 % on March 2019 to 15.37 % on March 2024 . This represents a CAGR of -8.38% over 6 years. a1#The Latest Trading Price of Dr Reddys Laboratories Ltd is ₹ 6892 as of 26 Jul 15:30 .a1#The Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 46069 crore on March 2019 to ₹ 102679 crore on March 2024 . This represents a CAGR of 14.29% over 6 years. a1#The Revenue of Dr Reddys Laboratories Ltd changed from ₹ 6096 crore to ₹ 7314 crore over 8 quarters. This represents a CAGR of 9.54% a1#The EBITDA of Dr Reddys Laboratories Ltd changed from ₹ 1804 crore to ₹ 2032 crore over 8 quarters. This represents a CAGR of 6.12% a1#The Net Pr of Dr Reddys Laboratories Ltd changed from ₹ 1189 crore to ₹ 1309 crore over 8 quarters. This represents a CAGR of 4.96% a1#
Open Demat Account
Enter your mobile no. to continue
+91
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
Market Cap
₹ 114,348 Cr
EPS
₹ 330.4
P/E Ratio (TTM) *
20.7
P/B Ratio (TTM) *
4.0
DTE *
0.1
ROE *
19.7
ROCE *
24.1
Dividend Yield *
0.65
DPS *
40
Dividend Payout *
15.37
Ann.Dividend % *
800
* All values are consolidated
Last Updated time: 27 Jul 13:03 PM
* All values are consolidated
Last Updated time: 27 Jul 13:03 PM
Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.
Period | |
---|---|
Mar '19 | 26 |
Mar '20 | 14 |
Mar '21 | 19 |
Mar '22 | 31 |
Mar '23 | 26 |
Mar '24 | 15 |
* All values are a in %
Dividend Yield is a financial ratio that shows the annual dividend income relative to the market price of a share. It is calculated by dividing the dividend per share by the current market price per share, expressed as a percentage.
* All values are in %
Dr Reddys Laboratories Ltd
NSE: DRREDDY
PRICE
₹ 6892.15
37.95 (0.55%)
Last updated : 26 Jul 15:30
Strength
2
S
Weakness
2
W
Opportunity
0
O
Threats
1
T
Revenue
Profitability
Affordability
Liquidity
Dividend
A dividend is paid on common stock when a company has accumulated substantial profits over years, often seen as excess cash that doesn't need immediate use.
A quarterly dividend is paid to preferred stock owners, typically accumulating a fixed amount, and is earned on shares that function more like bonds.
Companies declare interim dividends before final full-year accounts are prepared, specifically in India, during the financial year from April to March of the following year.
A final dividend is issued after the year's accounts have been compiled. Aside from this, the following list highlights the most prevalent sorts of dividends:
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Period | |
---|---|
Mar '19 | 46069 |
Mar '20 | 51798 |
Mar '21 | 75095 |
Mar '22 | 71653 |
Mar '23 | 76961 |
Mar '24 | 102679 |
* All values are a in ₹crore
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.
Period | |
---|---|
Jun '22 | 6096 |
Sep '22 | 6387 |
Dec '22 | 6855 |
Mar '23 | 6461 |
Jun '23 | 6936 |
Sep '23 | 7222 |
Dec '23 | 7456 |
Mar '24 | 7315 |
* All values are a in ₹crore
PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.
Period | |
---|---|
Jun '22 | 1805 |
Sep '22 | 1954 |
Dec '22 | 2003 |
Mar '23 | 1680 |
Jun '23 | 2240 |
Sep '23 | 2328 |
Dec '23 | 2242 |
Mar '24 | 2032 |
* All values are a in ₹crore
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue
Period | |
---|---|
Jun '22 | 1189 |
Sep '22 | 1114 |
Dec '22 | 1244 |
Mar '23 | 960 |
Jun '23 | 1405 |
Sep '23 | 1482 |
Dec '23 | 1381 |
Mar '24 | 1310 |
* All values are a in ₹crore
Dr Reddy's Laboratories Ltd (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. In the year 1993, the company established Dr. Reddy's Research Foundation and initiated drug discovery programme. In the year 2003, they launched Ibuprofen, first generic product to be marketed under the 'Dr. Reddy's' label in the US. During the year 2010-11, the company acquired GlaxoSmithKline's (GSK) oral penicillin manufacturing facility located in Tennessee, USA. During the year, the company launched Cresp in India, the first biosimilar darbepoetin alfa in the world. This action follows the earlier inspections of these sites by the agency in November 2014, January 2015 and February 2015 respectively. On 8 February 2017, Dr. Reddy's Laboratories Ltd announced the expansion of its commercial operations in Europe with the introduction of its portfolio of generics in France. It is intended to be used for the prevention of surgical site infections, following non-emergency, elective colorectal surgery. Under the terms of the agreement, Encore will be responsible for the commercialization of DFD-06 in the United States. This entire portfolio has been transferred to the Company, along with related sales and marketing teams, the manufacturing plant located in Baddi, Himachal Pradesh, and employees. Based on the forensic investigation, no evidence was found of any data breaches leading to personally identifiable information. As of March 31, 2022, there were 90 generic filings awaiting approval with the US Food and Drug Administration (USFDA), comprising 87 ANDAs and 3 NDAs. Dr. Reddy's (WUXI) Pharmaceutical Co. Limited in China ceased to be a step-down subsidiary of the Company with effect from December 13, 2021, consequent to its liquidation.
Dr. Reddy's inks patent licensing agreement with Takeda
Dr. Reddy's Laboratories announced that it has entered into a non-exclusive patent licensi...
Read more
19 Jul 202409:46
Dr. Reddy's inks patent licensing agreement with Takeda to commercialise Vonoprazan in India
Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to tr...
Read more
19 Jul 202409:50
Dr Reddys Laboratories Ltd gains for fifth session
Dr Reddys Laboratories Ltd is up for a fifth straight session in a row. The stock is quoti...
Read more
08 Jul 202413:01
Dr Reddys Laboratories Ltd spurts 1.14%, up for third straight session
Dr Reddys Laboratories Ltd rose for a third straight session today. The stock is quoting a...
Read more
04 Jul 202413:05
Dr Reddy’s Lab jumps after arm inks pact to acquire Nicotinell brand
Dr. Reddy’s Laboratories SA will acquire all of the quotas of Northstar Switzerland SARL (...
Read more
27 Jun 202411:05
Dr Reddys Laboratories Ltd gains for fifth session
Dr Reddys Laboratories Ltd is up for a fifth straight session in a row. The stock is quoti...
Read more
26 Jun 202413:00
FAQs for dividends of Dr Reddys Laboratories Ltd
What is the current market price of Dr Reddys Laboratories Ltd Ltd as of July 27, 2024?
What dividend did Dr Reddys Laboratories Ltd declare in the last fiscal year?
What is the most recent dividend declared by Dr Reddys Laboratories Ltd?
How many times has Dr Reddys Laboratories Ltd declared dividends in the current fiscal year
How many times did Dr Reddys Laboratories Ltd declare dividends in the previous fiscal year?
Unlimited trading at just
Rs. 199